It appears the end has come for Jacobus Pharmaceutical’s Ruzurgi, a potassium channel blocker that had received an Orphan Drug designation from the FDA for treatment of Lambert-Eaton myasthenic syndrome (LEMS) in children age six to 16, but had yet to be approved.
Source: Drug Industry Daily